LAUSR

Non-invasive localization of lesions and specific targeted therapy are still the main challenges for inflammatory bowel disease (IBD). Ta, as a medical metal element, has been widely used in the treatment of different diseases because of its excellent physicochemical properties, but is still far from being explored in IBD. Here, Ta2 C modified with chondroitin sulfate (CS) (TACS) was evaluated as a highly targeted therapy nanomedicine for IBD. Specifically, TACS was modified with dual targeting CS functions due to IBD lesion-specific positive charges and high expression of CD44 receptor. Thanks to the acid stability, sensitive CT imaging function and strong ROS elimination ability, oral TACS can accurately locate and delineate IBD lesions through non-invasive CT imaging, and specifically targeted treat IBD effectively because high levels of ROS are a central factor in the progression of IBD. As expected, TACS has much better imaging and therapeutic effects than clinical CT contrast agent and first-line drug 5-aminosalicylic acid, respectively. The mechanism of TACS treatment mainly involves protection of mitochondria, elimination of oxidative stress, inhibiting macrophage M1 polarization, protection of intestinal barrier, and restoration of intestinal flora balance. Collectively, this work provides unprecedented opportunities for oral nanomedicines to targeted therapy of IBD. This article is protected by copyright. All rights reserved.